Ultragenyx Pharmaceutical, Inc. (RARE)

Over the past six months, Ultragenyx stock has declined significantly. Key events include FDA clearance for UX016, positive Phase 3 data for DTX301, FDA acceptance and priority review for DTX401, Q4 2025 earnings report, a workforce reduction, insider selling, analyst downgrades, and investor lawsuits. The company announced FDA clearance of its Investigational New Drug (IND) application for UX016. Ultragenyx announced positive 36-week data from its Phase 3 study of DTX301 AAV8 gene therapy. The U.S. FDA accepted and granted priority review for the Biologics License Application (BLA) for DTX401 AAV gene therapy. Ultragenyx reported Q4 2025 revenue of $207 million, beating estimates, but also a basic EPS loss of $1.29, missing analyst consensus. Ultragenyx announced a plan to cut 10% of its workforce. There has been significant insider selling over the past three months. Goldman Sachs downgraded Ultragenyx to Neutral from Buy. Several investor alerts and class action lawsuits have been announced on behalf of Ultragenyx Pharmaceutical Inc. investors.

Based on historical data, Ultragenyx stock has shown some seasonal tendencies, though with a "Poor" consistency score. February has historically been the strongest month, while March tends to be the weakest. Demand for Ultragenyx's products is likely driven more by disease prevalence, diagnosis rates, regulatory approvals, and treatment efficacy rather than traditional seasonal consumer demand fluctuations.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on identifying, developing, and commercializing novel products for serious rare and ultra-rare genetic diseases. The company operates in the biotechnology industry, targeting diseases with high unmet medical needs. Their therapeutic approaches include biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Major approved products include Crysvita for XLH and TIO, Mepsevii for MPS VII, Dojolvi for LC-FAOD, and Evkeeza for HoFH. The company also has a robust clinical-stage pipeline.

Ultragenyx has a global presence with offices and laboratories in 12 countries across North America, Europe, Asia, and Latin America. In the U.S., they have facilities in California, Florida, Massachusetts, Texas, and Utah. Their therapies are approved and sold in Canada, Latin America, Europe, and Japan, and their products are sold in 26 countries. The majority of their revenue is generated from North America.

Ultragenyx has a reputation as a biopharmaceutical company committed to developing novel products for serious rare and ultra-rare genetic diseases, with a focus on high unmet medical needs. The company emphasizes its purpose-driven approach and commitment to the rare disease community. However, recent financial challenges, insider selling activity, and investor lawsuits could impact its reputation.

Ownership of Ultragenyx stock is primarily dominated by institutional investors, holding approximately 58.83% to 97.67% of the company's stock. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Emil D. Kakkis, the founder and president, is the largest individual shareholder. Insider ownership generally accounts for a low single-digit percentage. Public Companies & Retail Investors hold a smaller percentage.